A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer

2025-524168-39-00 Protocol ​​MEN2501-01​ Human pharmacology (Phase I) - First administration to humans Authorised, recruiting

Start 13 Apr 2026 · Status Authorised, recruiting · 1 EU/EEA countries · 6 sites · Protocol ​​MEN2501-01​

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruiting
Participants planned 120
Countries 1
Sites 6

​​Platinum-Resistant ovarian cancer​

Key facts

Sponsor
Stemline Therapeutics Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
13 Apr 2026 → ongoing
Decision date (initial)
2026-03-23
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-524168-39-00
WHO UTN
U1111-1330-4197
ClinicalTrials.gov
NCT07226427

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

​​Platinum-Resistant ovarian cancer​

VersionLevelCodeTermSystem organ class
20.0 PT 10033128 Ovarian cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Stemline Therapeutics Inc.

Sponsor organisation
Stemline Therapeutics Inc.
Address
750 Lexington Avenue
City
New York
Postcode
10022-1200
Country
United States

Scientific contact point

Organisation
Stemline Therapeutics Inc.
Contact name
​​Clinical Development and Clinical Operations​

Public contact point

Organisation
Stemline Therapeutics Inc.
Contact name
​​Clinical Development and Clinical Operations​

Locations

1 EU/EEA country · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Authorised, recruiting 23 6
Rest of world
United States, Australia
97

Investigational sites

Spain

6 sites · Authorised, recruiting
Hospital Universitario Hm Sanchinarro
034-04: Oncology, Calle Ona 10, 28050, Madrid
Hospital Universitario Quironsalud Madrid
034-01: Medical Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario 12 De Octubre
034-06: Medical Oncology, Avenida De Cordoba Sn, 28041, Madrid
Hospital Clinico Universitario De Valencia
034-05: Oncologia Médica y Hematologia, Avenida Blasco Ibanez 17, 46010, Valencia
Clinica Universidad De Navarra
034-02: Oncología, Calle Marquesado De Santa Marta 1, 28027, Madrid
Instituto Oncologico Dr. Rosell S.L.
034-03: Oncology, Calle De Sabino Arana Num. 5, 08028, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2026-04-13

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-11-24 Spain Acceptable with conditions
2026-03-20
2026-03-23